Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 1/20 | 0.64 |
| ▸ | ELOC | Q15369 | 1/20 | 0.64 |
| ▸ | ELOB | Q15370 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL8101571 | 0.96 | VHL (0.60) | VHLELOCELOBKDM4EALDH1A1 | |
| SCHEMBL5203764 | 0.89 | VHL (0.51) | VHLELOCELOBKDM4EALDH1A1 | |
| SCHEMBL13135 | 0.85 | KDM4E (0.58) | VHLELOCELOBKDM4EALDH1A1 | |
| SCHEMBL30714352 | 0.85 | KDM4E (0.58) | VHLELOCELOBKDM4EALDH1A1 | |
| SCHEMBL7992397 | 0.82 | KDM4E (0.48) | VHLELOCELOBKDM4EALDH1A1 | |
| SCHEMBL6592045 | 0.81 | VHL (0.64) | VHLELOCELOBKDM4EALDH1A1 | |
| SCHEMBL30829218 | 0.81 | S100A4 (0.43) | VHLELOCELOBCTSLTDP1 | |
| SCHEMBL5329304 | 0.81 | S100A4 (0.43) | VHLELOCELOBCTSLTDP1 | |
| SCHEMBL12743 | 0.78 | VHL (0.64) | VHLELOCELOBKDM4EALDH1A1 | |
| SCHEMBL69544 | 0.78 | VHL (1.00) | VHLELOCELOBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| US-20260001886-A1 | ENPP1 INHIBITORS I | RE VENTURES I LLC (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025233863-A1 | ENPP1 INHIBITORS | RE VENTURES I, LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025136671-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4540230-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119136619-A | Perovskite solar cell and chemical induction surface reconstruction preparation method | 陕西师范大学 | 2024-12-13 | — | — | CN | disclosed |
| US-20240246950-A1 | Anilino-Pyrazole Derivatives, Compositions and Methods Thereof | Ensem Therapeutics (US) | 2024-07-25 | — | — | US | disclosed |
| US-12037501-B2 | Photocurable ink composition and image recording method | FUJIFILM CORPORATION (JP) | 2024-07-16 | — | — | US | disclosed |
| US-12037501-B2 | Photocurable ink composition and image recording method | FUJIFILM CORPORATION (JP) | 2024-07-16 | — | — | US | disclosed |
| EP-3689981-B1 | ACTINIC-RAY-CURABLE INK-JET INK, LIGHT-SHIELDING FILM, AND PRODUCTION METHOD FOR LIGHT-SHIELDING FILM | FUJIFILM CORP (JP) | 2024-07-10 | — | — | EP | disclosed |
| EP-0836600-A1 | HERBICIDAL KETALS AND SPIROCYCLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-04-22 | — | — | EP | disclosed |
| US-5728846-A | RETENOIDS, RETINOID ACTIVITY; AGONISTS, ANTAGONISTS | ALLERGAN (US) | 1998-03-17 | — | — | US | disclosed |
| WO-1997009297-A2 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | VISION PHARMACEUTICALS L.P. (US) | 1997-03-13 | — | — | WO | disclosed |
| WO-1997001550-A1 | HERBICIDAL KETALS AND SPIROCYCLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-01-16 | — | — | WO | disclosed |
| US-4282229-A | FOR DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
| US-4258054-A | ANTIDIABETIC | PFIZER INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4210756-A | Tetrahydroquinoline hydantoins for chronic diabetic complications | PFIZER INC. (US) | 1980-07-01 | — | — | US | disclosed |
| US-4209630-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1980-06-24 | — | — | US | disclosed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4117230-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001886-A1 | ENPP1 INHIBITORS I | ENPP1, ENPP2, ENPP3 | VHL 1464/4885ELOC 414/4885ELOB 648/4885 |
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | DPP9, DPP7, DPP4 | VHL 1856/4885ELOC 2247/4885ELOB 3976/4885 |
| US-20240246950-A1 | Anilino-Pyrazole Derivatives, Compositions and Methods Thereof | CDK2, CDK3, CDK4 | VHL 675/4885ELOC 1429/4885ELOB 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.